Depending on the active ingredient itself induced diseases as interstitial fibrosis, organizing pneumonia, asthma, non-cardiac pulmonary edema, pleural effusions, pulmonary eosinophilia, pulmonary veno-occlusive diseases or bleeding express drug (see Table: Substances with toxic pulmonary effects).
Drug-induced lung disease is a generic term for a heterogeneous group of disorders that represent a frequent clinical problem in which a patient develops no pre-existing lung disease respiratory symptoms, changes in chest x-ray, impaired lung function, histological changes or some of these findings in relation to a drug therapy , should cause lung disease than 150 drugs or drug groups. The pathological mechanism is rarely known, but many drugs are to cause an allergic reaction. Some medications (eg. As nitrofurantoin) can cause different injury patterns in different patients. Depending on the active ingredient itself induced diseases as interstitial fibrosis, organizing pneumonia, asthma, non-cardiac pulmonary edema, pleural effusions, pulmonary eosinophilia, pulmonary veno-occlusive diseases or bleeding express drug (see Table: Substances with toxic pulmonary effects). Substances with toxic effects pulmonary disease drug or substance asthma, aspirin, beta blockers (eg. B. timolol), cocaine, dipyridamole, i.v. Hydrocortisone (rare in patients with asthma who are sensitive to aspirin), IL-2, methylphenidate, nitrofurantoin, protamine, sulfasalazine, vinca alkaloids organizing (with mitomycin-C) pneumonia amiodarone, bleomycin, cocaine, cyclophosphamide, methotrexate, minocycline, mitomycin C, penicillamine, sulfasalazine, azathioprine plus tetracycline hypersensitivity pneumonitis. 6-mercaptopurine, busulfan, fluoxetine, irradiation Interstitial pneumonitis or fibrosis amphotericin B, bleomycin, busulfan, carbamazepine, chlorambucil, cocaine, cyclophosphamide, diphenylhydantoin, flecainide, heroin, melphalan, Methadone, methotrexate, methylphenidate, methysergide, mineral oil ((via microaspiration chronic), nitrofurantoin, nitrosureas, procarbazine, silicone s.c. Injection), tocainide, vinca alkaloids (Nichtkardiogenes with mitomycin-C) pulmonary edema beta-adrenergic agonists (eg. B. ritodrine, terbutaline), chlordiazepoxide, cocaine, cytarabine, “ethiodized oil” (iv and chronic microaspiration), gemcitabine, heroin, hydrochlorothiazide, methadone, mitomycin-C, phenothiazines, protamine, sulfasalazine, tocolytic agents, tricyclic antidepressants, tumor necrosis factor, vinca alkaloids Parenchymal (mitomycin-C) circulation anticoagulants, azathioprine plus. 6-mercaptopurine, cocaine, mineral oil (about chronic microaspiration), nitrofurantoin , radiation pleural effusion amiodarone, Anticoagulants, bleomycin, bromocriptine, busulfan, granulocyte-macrophage colony stimulating factor, IL-2, methotrexate, methysergide, mitomycin-C, nitrofurantoin, para-aminosalicylic acid, procarbazine, radiation, tocolytic agents Pulmonary infiltrates with eosinophilia amiodarone, amphotericin B, bleomycin, carbamazepine, diphenylhydantoin, ethambutol, etoposide, granulocyte-macrophage colony-stimulating factor, isoniazid, methotrexate, minocycline, mitomycin-C, nitrofurantoin, para-aminosalicylic acid, procarbazine, radiation, sulfasalazine, sulfonamides, tetracycline, trazodone Vascular lung diseases appetite suppressant (eg. As dexfenfluramine, fenfluramine, phentermine), busulfan, cocaine, heroin, methadone, methylphenidate, nitrosoureas, radiation Diagnosis is based on clinical improvement after discontinuation of the suspect drug and, if practical, re-provocation testing. Treatment discontinuation of the drug The treatment consists in the discontinuation of the drug, that causes pulmonary disease .. prevention is often done before or at the beginning of therapy with a lung toxic drug as a screening test a pulmonary function test, the benefit, however, is not proven for the prediction or early detection of toxicity.